Brought to you by:
The top 10 most popular Vascular Specialist stories of March 2023
In March 2023, the Vascular Specialist stories grabbing readers’ attention were a response to a February letter addressing vascular surgeons’ use of social media; an interview with an advocate for more carefully considered use of venous stents; the publication of the…
Former SVS President William Abbott, 1997–98, dies at 86
William Martin Abbott, MD, former president of the Society for Vascular Surgery (SVS), died peacefully in his home Jan. 9 after a brief illness. He was 86. Abbott grew up in San Francisco and graduated from Stanford University and Stanford…
SCVS 2023: DAPT linked to better post-TCAR outcomes versus other drug regimens
Recent data presentations have revealed reduced risks of stroke and mortality among transcarotid artery revascularization (TCAR) patients who receive dual antiplatelet therapy (DAPT)—both preoperatively and at discharge—as compared to other drug regimens. Researchers believe these findings underscore the importance of…
Computational model found to predict early aortic abdominal aneurysm rupture
In Physics of Fluids, by AIP Publishing, researchers from the Indian Institute of Technology (BHU) Varanasi and Indian Institute of Technology Kanpur made a computational model of the cardiovascular system in order to predict early abdominal aortic aneurysm (AAA) rupture…
SCVS 2023: DAPT shows higher survival rate in patients with low WIfI scores, study indicates
A retrospective cohort study presented at the 2023 Society for Clinical Vascular Surgery (SCVS) Annual Symposium in Miami (March 25–29) has found lower-extremity bypass patients who received dual antiplatelet therapy or anticoagulation (DAPT/AC) postoperatively had a higher 30-day survival rate.…
Getting medical devices to market: The future might not be now, says regulatory expert
The development of medical devices in the vascular space faces increasing challenges amid moves afoot at the Food and Drug Administration (FDA), according to a leading regulatory expert in the field. Among the developmental vehicles currently caught in the crosshairs…
Results from PROMISE II pivotal trial published, reinforcing ‘ transformational value’ of deep vein arterialization in no-option CLTI patients
Results from the PROMISE II pivotal trial investigating transcatheter arterialization of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischemia (CLTI) patients were today published in the New England Journal of Medicine (NEJM). The publication confirmed…
DAPT linked to better post-TCAR outcomes versus other drug regimens
Dual antiplatelet therapy (DAPT) has demonstrated improved clinical outcomes, including reduced in-hospital stroke and mortality risks, compared to other medication regimens in carotid disease patients who undergo stent placement via a transcarotid artery revascularization (TCAR) procedure. This is the key…
SCVS 2023: Endovascular-first or -only approach to all CLTI patients ‘is not evidence-based care’
Michael S. Conte, MD, one of the foremost experts in the field of peripheral arterial disease (PAD), took attendees of the 2023 annual meeting of the Society for Clinical Vascular Surgery (SCVS) in Miami on a journey through the decades…
Short neck AAAs: ‘Choosing what is best for the patient’
Navigating cases of abdominal aortic aneurysm (AAA) with short neck anatomy poses a serious challenge to vascular surgeons, but the list of potential options available to carry out repairs are numerous—and decision-making can be optimized by using a bespoke algorithm.…